Практические Рекомендации По Профилактике И Лечению Тошноты И Рвоты У Онкологических Больных

Владимирова, Л. Ю.; Gladkov, Oleg; Koroleva, Irina; Румянцев, А. А.; Семиглазова, Т. Ю.; Трякин, А. А.; Кутукова, Светлана; Овчинникова, Е. Г.; Novikova, Olga; Корниецкая, А. Л.

doi:10.18027/2224-5057-2021-11-3s2-37

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Первым препаратом класса ингибиторов NK1-рецепторов стал апрепитант, одобренный FDA в 2003 г. 1 Для клинической практики одобрены апрепитант и его внутривенная форма фосапрепитант. Фосапрепитант -водорастворимое пролекарство апрепитанта.…”

Section: антагонисты Nk1-рецепторовunclassified

“…Неконтролируемая (breakthrough -прорывная) ТиР развивается на фоне адекватной антиэметической профилактики и требует дополнительной коррекции. Рефрактерная ТиР возникает на последующих циклах химиотерапии при неэффективности противорвотной профилактики и/или препаратов резерва на предыдущих курсах лечения [1].…”

Section: Introductionunclassified

“…По способности противоопухолевого агента в виде монотерапии вызывать ТиР препараты разделены на 4 уровня эметогенности противоопухолевых препаратов (высоко-, умеренно, низко-и минимально эметогенные). Высокоэметогенными считаются режимы химиотерапии, при которых частота развития рвоты более 90%, умеренно эметогенными -30-90%, низкоэметогенными -10-30%, минимально эметогенными -менее 10% [1,3]. Эметогенный потенциал препаратов для внутривенного введения определяется, как правило, для режима однодневного введения, т. е. эметогенность разовой дозы.…”

Section: Introductionunclassified

“…Комбинация умеренно эметогенных противоопухолевых препаратов может повышать эметогенность режима в целом. Так, режим АС (доксорубицин + циклофосфамид), который используется при раке молочной железы с 1970 г., формально является умеренно эметогенным (по наиболее эметогенному препарату), но в настоящее время отнесен к высокоэметогенным режимам [1,[4][5][6].…”

Section: Introductionunclassified

“…Увеличивают риск развития ТиР женский пол, возраст пациента моложе 60 лет, ТиР на предшествующем цикле, сочетание в одном режиме химиотерапии антрациклинов и препаратов платины [1,[4][5][6].…”

Section: Introductionunclassified

See 4 more Smart Citations

Oral combination of netupitant and palonosetron for the of nausea and vomiting induced by chemotherapy

Koroleva

Kopp

2022

Medicinskij sovet

View full text Add to dashboard Cite

Nausea and vomiting are the most frequent and painful adverse event of chemotherapy. Uncontrolled nausea and vomiting lead to a significant decrease in the quality of life of patients, nutritional insufficiency, breaking of the chemotherapy therapy regimen. Nausea and vomiting worsen the result of chemotherapy and the prognosis of the disease. In clinical studies of antiemetic drugs the “complete response” is used as the primary endpoint. The complete redponse is the absence of nausea and vomiting and the need for additional antiemetic drugs. The oral combination of netupitant and palonosetron is a modern drug for the prevention of nausea and vomiting induced by chemotherapy. This combination includes a highly selective anatagonist of NK1-receptors netupitant at a dose of 300 mg and an antagonist of 5-HT3 receptors palonosetron at a dose of 0.5 mg. The combination of net-upitant and palonosetron has high compliance, it is prescribed once before chemotherapy. The combination of netupitant and palonosetron makes it possible to achieve complete control of acute (0-24 hours) and delayed (24-120 hours) nausea and vomiting with highly emetogenic chemotherapy. In a randomized trial (n = 1455) with AC chemotherapy (doxorubicin + cyclophosphamide), the combination of netupitant and palonosetron resulted in a complete response during the general phase (0-120 hours) in 73.3% of patients. 78.4% of patients with the combination of netupitant and palonosteron experienced “no effect on daily life” due to nausea and vomiting. In an observational study of real clinical practice (n = 1197), the combination of netupitant and palonosetron in the AC chemotherapy regimen (doxorubicin + cyclophosphamide) had a complete response during the general phase (0-120 hours) in 81% of patients. Adverse events when using the combination of netupitant and palonosetron are minimal, constipation was noted in 1-8% of cases, headache in 1.4-3.6% of cases.

show abstract

Section: антагонисты Nk1-рецепторовunclassified

Section: Introductionunclassified

See 3 more Smart Citations

Oral combination of netupitant and palonosetron for the of nausea and vomiting induced by chemotherapy

Koroleva

Kopp

2022

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Prevention of induced nausea and vomiting in patients with malignant blood disorders. Experience of using netupitant/palonosetron (Akynzeo)

Ryabukhina

Zeynalovа

Тимофеева

et al. 2022

jour

View full text Add to dashboard Cite

Supporting therapy is a necessary component of successful antitumor treatment in patients with both solid tumors and malignant blood disorders. Adherence to administration protocol for antiemetic drugs aimed at prevention of induced gastrointestinal complications (nausea and vomiting), allows to improve patients' quality of life and treatment compliance. Development of a combination antiemetic drug (netupitant/palonosetron) simultaneously affecting 2 main mechanisms of nausea and vomiting as well as its easy administration allowed to significantly improve control of these complications in patients with solid tumors and patients with malignant blood disorders.We present a literature review on the effectiveness of netupitant/palonosetron and describe our own experience of using this antiemetic drug for prevention of chemotherapy-induced nausea and vomiting.

show abstract

Priorities in choosing prokinetic for patients with functional dyspepsia: Focus on itopride

Babich

Зубарева

Ketova

2022

Medicinskij alfavit

View full text Add to dashboard Cite

Functional dyspepsia is a widespread disease with many symptoms that reduce the patient's quality of life. The effectiveness of prokinetics, including in combination with proton pump inhibitors, has a high level of scientific evidence in the treatment of functional dyspepsia. The effectiveness of itopride hydrochloride is determined by a dual mechanism of action: antagonism to D 2-dopamine receptors and inhibition of acetylcholinesterase. The drug exceeds of metoclopramide and domperidone in safety in relation to cardiac and neurological disorders. Itopride hydrochloride is not expected to have pharmacokinetic interactions with other drugs metabolized by the CYP3A4 system. In addition to functional dyspepsia, itopride hydrochloride is indicated in the treatment of chronic gastritis, gastrointestinal symptoms associated with gastric dysmotility or delayed gastric emptying, such as bloating, rapid satiety, a feeling of fullness in the stomach after eating, pain or discomfort in the epigastric region, loss of appetite, heartburn, nausea and vomiting. The pharmacoeconomic analysis shows an advantage of Itopride-SZ in comparing of the direct cost of it with the original and several generic drugs. In this way, it allows recommend Itopride-SZ as an affordable drug for various cohorts of patients.

show abstract

Практические Рекомендации По Профилактике И Лечению Тошноты И Рвоты У Онкологических Больных

Cited by 3 publications

References 0 publications

Oral combination of netupitant and palonosetron for the of nausea and vomiting induced by chemotherapy

Oral combination of netupitant and palonosetron for the of nausea and vomiting induced by chemotherapy

Prevention of induced nausea and vomiting in patients with malignant blood disorders. Experience of using netupitant/palonosetron (Akynzeo)

Priorities in choosing prokinetic for patients with functional dyspepsia: Focus on itopride

Contact Info

Product

Resources

About